As reimbursements decline, will care that dermatologists provide suffer?
With the presidential election behind us and myriad changes about to hit healthcare, dermatologists need to anticipate cuts in reimbursement by not only government, but also private, insurers. And if dermatologists are to combat the impact these declining reimbursements may have on their practices, they need to start implementing more aggressive patient education and retention efforts now.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.